NOVN
Novan, Inc. [NOVN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NOVN Stock Summary
In the News
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive Vice President & Chief Operating Officer John Gay - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Jeff Jones - Oppenheimer Jonathan Aschoff - Roth Capital Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello and welcome to the Novan Inc. Quarterly Update Conference Call and Webcast.
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
Novan to Report Full Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief Financial Officer John Donofrio - Chief Operating Officer and President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript
Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donofrio - EVP, COO & President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Brian Dolliver - Brookline Capital Markets Jonathan Aschoff - ROTH Capital Partners Oren Livnat - H.C. Wainwright & Co. John Vandermosten - Zacks Small-Cap Research Jennifer Kim - Cantor Fitzgerald & Co. Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast.
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum –
Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q1 2022 Results - Earnings Call Transcript
Novan, Inc. (NASDAQ:NOVN ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President and Chief Executive Officer John Donofrio - Chief Operating Officer, Novan and President, EPI Health John Gay - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital John Vandermosten - Zacks Jonathan Aschoff - Roth Capital Partners Operator Hello and welcome to the Novan, Incorporated Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
NOVN Financial details
NOVN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.32 | 1.71 | 0.43 | 0.17 | 1.07 | |
| Net income per share | 1.25 | -11.72 | -3.05 | -1.69 | -0.89 | |
| Operating cash flow per share | -11.1 | -7.57 | -3.14 | -1.45 | -1.4 | |
| Free cash flow per share | -11.53 | -7.73 | -3.21 | -1.98 | -1.6 | |
| Cash per share | 3.18 | 5.22 | 3.63 | 2.76 | 0.56 | |
| Book value per share | 2.02 | -9.06 | 0.3 | 1.07 | 0.21 | |
| Tangible book value per share | 1.99 | -9.09 | 0.29 | 1.07 | -1.22 | |
| Share holders equity per share | 2.02 | -9.06 | 0.3 | 1.07 | 0.21 | |
| Interest debt per share | 3.51 | 2.39 | 0.1 | 0.5 | 0.24 | |
| Market cap | 21.41M | 82.96M | 80.33M | 71.16M | 32.15M | |
| Enterprise value | 21.24M | 75.51M | 45.41M | 27.69M | 23.76M | |
| P/E ratio | 6.66 | -2.7 | -2.66 | -2.47 | -1.64 | |
| Price to sales ratio | 3.57 | 18.53 | 19.09 | 25.22 | 1.36 | |
| POCF ratio | -0.75 | -4.17 | -2.59 | -2.87 | -1.04 | |
| PFCF ratio | -0.72 | -4.09 | -2.53 | -2.1 | -0.91 | |
| P/B Ratio | 4.12 | -3.49 | 26.98 | 3.88 | 6.98 | |
| PTB ratio | 4.12 | -3.49 | 26.98 | 3.88 | 6.98 | |
| EV to sales | 3.54 | 16.87 | 10.79 | 9.81 | 1.01 | |
| Enterprise value over EBITDA | -2.13 | -2.66 | -1.89 | -0.91 | -0.7 | |
| EV to operating cash flow | -0.74 | -3.8 | -1.46 | -1.12 | -0.77 | |
| EV to free cash flow | -0.71 | -3.72 | -1.43 | -0.82 | -0.68 | |
| Earnings yield | 0.15 | -0.37 | -0.38 | -0.41 | -0.61 | |
| Free cash flow yield | -1.39 | -0.24 | -0.39 | -0.48 | -1.09 | |
| Debt to equity | 1.54 | -0.26 | 0.32 | 0.47 | 0.85 | |
| Debt to assets | 0.3 | 0.22 | 0.02 | 0.12 | 0.04 | |
| Net debt to EBITDA | 0.02 | 0.26 | 1.45 | 1.43 | 0.25 | |
| Current ratio | 1.03 | 1.22 | 5.06 | 4.85 | 0.91 | |
| Interest coverage | -27.28 | -15.34K | 0 | 0 | -24.37 | |
| Income quality | 2.26 | 0.65 | 1.06 | 0.83 | 0.99 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.92 | 2.33 | 2.68 | 4.37 | 0 | |
| Research and developement to revenue | 3.85 | 5.62 | 4.71 | 7.23 | 0.68 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0.35 | |
| Capex to operating cash flow | 0.04 | 0.02 | 0.02 | 0.37 | 0.14 | |
| Capex to revenue | -0.18 | -0.09 | -0.15 | -3.21 | -0.18 | |
| Capex to depreciation | -0.67 | -0.21 | -0.55 | -26.31 | -1.54 | |
| Stock based compensation to revenue | 0.37 | 0.41 | 0.31 | 0.1 | 0.08 | |
| Graham number | 7.52 | 48.89 | 4.55 | 6.39 | 2.04 | |
| ROIC | 0.34 | 2.74 | -7.91 | -0.95 | -1.77 | |
| Return on tangible assets | 0.12 | -1.06 | -0.65 | -0.42 | -0.33 | |
| Graham Net | -5.03 | -14.8 | -0.44 | 0.06 | -2.56 | |
| Working capital | 289K | 2.83M | 35.31M | 42.98M | -4.03M | |
| Tangible asset value | 5.12M | -23.86M | 2.9M | 18.24M | -26.93M | |
| Net current asset value | -11.81M | -37.16M | 155K | 3.49M | -43.36M | |
| Invested capital | 1.54 | -0.26 | 0.32 | 0.47 | 0.85 | |
| Average receivables | 0 | 209.5K | 2.64M | 4.67M | 13.24M | |
| Average payables | 864.5K | 1.43M | 1.4M | 1.68M | 7.93M | |
| Average inventory | 0 | 0 | 0 | 1.23M | 1.83M | |
| Days sales outstanding | 0 | 34.16 | 421.81 | 578.54 | 340.16 | |
| Days payables outstanding | 19.8 | 23.23 | 0 | 0 | 677.12 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 59.16 | |
| Receivables turnover | 0 | 10.68 | 0.87 | 0.63 | 1.07 | |
| Payables turnover | 18.44 | 15.71 | 0 | 0 | 0.54 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 6.17 | |
| ROE | 0.62 | 1.29 | -10.13 | -1.57 | -4.25 | |
| Capex per share | -0.43 | -0.16 | -0.07 | -0.53 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.1 | 0.3 | 0.21 | 0.48 | 0.11 | |
| Net income per share | -0.72 | -0.45 | -0.1 | 1.21 | -0.54 | |
| Operating cash flow per share | 0.04 | -0.55 | -0.39 | -0.5 | -0.16 | |
| Free cash flow per share | -0.01 | -0.64 | -0.4 | -0.55 | -0.16 | |
| Cash per share | 1.88 | 1.85 | 0.61 | 0.56 | 0.48 | |
| Book value per share | 0.31 | 0.61 | 0.28 | 0.21 | -0.11 | |
| Tangible book value per share | -1.65 | -1.15 | -1.04 | -1.22 | -1.3 | |
| Share holders equity per share | 0.31 | 0.61 | 0.28 | 0.21 | -0.11 | |
| Interest debt per share | 1.1 | 1.04 | 0.19 | 0.18 | 0.16 | |
| Market cap | 74.19M | 47.1M | 45.74M | 32.15M | 33.95M | |
| Enterprise value | 59.33M | 30.23M | 34.9M | 23.76M | 25.26M | |
| P/E ratio | -1.37 | -1.31 | -4.68 | 0.3 | -0.6 | |
| Price to sales ratio | 39.21 | 7.66 | 8.97 | 3.07 | 11.33 | |
| POCF ratio | 96.85 | -4.24 | -4.85 | -2.89 | -7.99 | |
| PFCF ratio | -457.95 | -3.63 | -4.65 | -2.64 | -7.95 | |
| P/B Ratio | 12.61 | 3.85 | 6.77 | 6.98 | -12.01 | |
| PTB ratio | 12.61 | 3.85 | 6.77 | 6.98 | -12.01 | |
| EV to sales | 31.36 | 4.91 | 6.85 | 2.27 | 8.43 | |
| Enterprise value over EBITDA | -4.55 | -3.81 | -4.04 | -7.96 | -2.02 | |
| EV to operating cash flow | 77.45 | -2.72 | -3.7 | -2.14 | -5.94 | |
| EV to free cash flow | -366.22 | -2.33 | -3.55 | -1.95 | -5.91 | |
| Earnings yield | -0.18 | -0.19 | -0.05 | 0.83 | -0.42 | |
| Free cash flow yield | 0 | -0.28 | -0.22 | -0.38 | -0.13 | |
| Debt to equity | 3.51 | 1.67 | 0.6 | 0.85 | -1.36 | |
| Debt to assets | 0.18 | 0.18 | 0.05 | 0.04 | 0.05 | |
| Net debt to EBITDA | 1.14 | 2.13 | 1.26 | 2.81 | 0.69 | |
| Current ratio | 1.25 | 1.4 | 0.97 | 0.91 | 0.74 | |
| Interest coverage | -100.2 | -14.38 | -15.15 | -49.4 | -48.62 | |
| Income quality | -0.06 | 1.25 | 1.56 | 3.67 | 0.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 3.35 | |
| Research and developement to revenue | 2.55 | 0.51 | 0.84 | 0.36 | 1.61 | |
| Intangibles to total assets | 0.33 | 0.31 | 0.39 | 0.35 | 0.39 | |
| Capex to operating cash flow | -1.21 | 0.17 | 0.04 | 0.1 | 0.01 | |
| Capex to revenue | -0.49 | -0.3 | -0.08 | -0.1 | -0.01 | |
| Capex to depreciation | -4.26 | -2.35 | -0.45 | -1.25 | -0.03 | |
| Stock based compensation to revenue | 0.2 | 0.07 | 0.1 | 0.05 | 0.14 | |
| Graham number | 2.25 | 2.47 | 0.79 | 2.38 | 1.15 | |
| ROIC | -0.44 | -0.24 | -0.26 | 2.68 | -2.77 | |
| Return on tangible assets | -0.18 | -0.11 | -0.05 | 0.45 | -0.29 | |
| Graham Net | -3.08 | -2.49 | -2.04 | -2.56 | -2.26 | |
| Working capital | 11.71M | 17.8M | -1000K | -4.03M | -11.22M | |
| Tangible asset value | -31.07M | -23.19M | -25.33M | -26.93M | -33.88M | |
| Net current asset value | -47.49M | -40.09M | -41.88M | -43.36M | -49.94M | |
| Invested capital | 3.51 | 1.67 | 0.6 | 0.85 | -1.36 | |
| Average receivables | 10.24M | 17.12M | 16.55M | 18.44M | 17.92M | |
| Average payables | 3.46M | 5.75M | 5.42M | 8.88M | 14.01M | |
| Average inventory | 739K | 1.52M | 1.37M | 1.19M | 1.16M | |
| Days sales outstanding | 761.72 | 266.46 | 262.78 | 189.17 | 415.63 | |
| Days payables outstanding | 2.08K | 232.79 | 254.63 | 394.88 | 1K | |
| Days of inventory on hand | 645.73 | 53.72 | 73.63 | 34.5 | 78.16 | |
| Receivables turnover | 0.12 | 0.34 | 0.34 | 0.48 | 0.22 | |
| Payables turnover | 0.04 | 0.39 | 0.35 | 0.23 | 0.09 | |
| Inventory turnover | 0.14 | 1.68 | 1.22 | 2.61 | 1.15 | |
| ROE | -2.3 | -0.74 | -0.36 | 5.77 | 4.99 | |
| Capex per share | -0.05 | -0.09 | -0.02 | -0.05 | 0 |
NOVN Frequently Asked Questions
What is Novan, Inc. stock symbol ?
Novan, Inc. is a US stock , located in Durham of Ca and trading under the symbol NOVN
What is Novan, Inc. stock quote today ?
Novan, Inc. stock price is $0.056 today.
Is Novan, Inc. stock public?
Yes, Novan, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.04M
- Market Capitalization 2.64M
- Employee 90
- CEO Ms. Paula Brown Stafford M.P.H.
- Headquarters Durham,CA,US
- IPO Date 2016-09-21
-
Website
https://www.novan.com 
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
